Search

Sarepta Therapeutics and Codiak BioSciences Collaborate to Research and Develop Exosome-Based Therapeutics for Rare Diseases
Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Casimersen (SRP-4045) for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 45
Sarepta Therapeutics to Participate in Upcoming Investor Conferences
A life in motion: One family’s journey with Duchenne
Muscle MRI in Duchenne: What it shows and why it matters
Community Bulletin: Update on FDA Acceptance of sNDAs for Exon-Skipping Therapies
Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Time to Rise From Floor: What it can tell us about when to act in Duchenne
Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results